Boosting CAR t: early second dose may keep childhood leukemia at bay
NCT ID NCT05460533
First seen Nov 01, 2025 · Last updated Jun 07, 2026 · Updated 30 times
Summary
This study tests whether giving a second dose of the CAR T-cell therapy tisagenlecleucel early can keep the immune system's B cells low for at least 6 months in children and young adults with relapsed B-cell acute lymphoblastic leukemia. The goal is to reduce the chance of the cancer coming back. The trial involves 30 participants who already received their first dose and have extra doses available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado (Data Collection Only)
Aurora, Colorado, 80045, United States
-
Children's Hospital of Los Angeles (Data Collection Only)
Los Angeles, California, 90027, United States
-
Cincinnati Children's Hospital Medical Center (Data Collection Only)
Cincinnati, Ohio, 45229, United States
-
Johns Hopkins University (Data Collection Only)
Baltimore, Maryland, 21287, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Stanford University (Data Collection Only)
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.